Abstract
Bullous pemphigoid (BP) is a common autoimmune blistering disorder with unknown etiology. Recently, increasing numbers of BP cases which developed under the medication with dipeptidyl peptidase-4 inhibitors (DPP4i), widely used antihyperglycemic drugs, have been reported in published works. Here, we report a case of DPP4i (teneligliptin)-associated BP that developed in a 70-year-old Japanese man. Interestingly, the patient had acquired reactive perforating collagenosis (ARPC), which is also known to be associated with the onset of BP. In the present case, clinical, histopathological and immunological findings suggested that DPP4i rather than ARPC was associated with the onset of BP.
Keywords:
acquired reactive perforating collagenosis; bullous pemphigoid; diabetes mellitus; dipeptidyl peptidase-4 inhibitors; full-length BP180 enzyme-linked immunoassay.
© 2018 Japanese Dermatological Association.
MeSH terms
-
Aged
-
Autoantigens / immunology
-
Biopsy
-
Collagen Diseases / diagnosis
-
Collagen Diseases / etiology*
-
Collagen Diseases / pathology
-
Collagen Type XVII
-
Diabetes Mellitus / drug therapy*
-
Dipeptidyl-Peptidase IV Inhibitors / adverse effects*
-
Drug Substitution / methods
-
Enzyme-Linked Immunosorbent Assay
-
Glycoside Hydrolase Inhibitors / therapeutic use
-
Humans
-
Inositol / analogs & derivatives
-
Inositol / therapeutic use
-
Male
-
Non-Fibrillar Collagens / immunology
-
Pemphigoid, Bullous / chemically induced
-
Pemphigoid, Bullous / complications*
-
Pemphigoid, Bullous / immunology
-
Pemphigoid, Bullous / pathology
-
Pyrazoles / adverse effects
-
Skin / immunology
-
Skin / pathology
-
Thiazolidines / adverse effects
Substances
-
3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine
-
Autoantigens
-
Dipeptidyl-Peptidase IV Inhibitors
-
Glycoside Hydrolase Inhibitors
-
Non-Fibrillar Collagens
-
Pyrazoles
-
Thiazolidines
-
Inositol
-
voglibose